Skip to main content

The weight-loss drugs are coming for these companies — but here’s why Coke, others, may be spared, says JPMorgan

JPMorgan says the weight-loss drug industry is now a "$100 billion plus opportunity." Coke is one of the stocks they say is likely to get hit less hard.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.